Deutsch-Österreichische Richtlinien zur Antiretroviralen Therapie der HIV-Infektion (Juli 2002)

  • J. L’age-Stehr
  • E. B. Helm
  • H. D. Peters
  • L. Nolde


Die Erfolge der antiretroviralen Therapie sind auch nach Erscheinen der letzten Version dieser Richtlinien weiterhin klar zu sehen. Die Hemmung der Virus-replikation durch eine antiretrovirale Therapie verhindert die Krankheitsprogression, fuhrt zur Rückbildung HIV-bedingter Symptome und zu einer klinisch relevanten Immunrekonstitution (l-4). Die Prognose HIV-infizierter Patienten hat sich hierdurch dramatisch verbessert (5). Gerade die bessere Wirksamkeit der heute verfügbaren antiretroviralen Kombinationstherapien in Kombination mit den Nebenwirkungen dieser Therapien hat jedoch die Diskussion über den idealen Zeitpunkt des Beginns einer Therapie der HIV-lnfektion erneut angefacht.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Mellors JW, Munoz A, Giorgi JV, et al.: Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Annals of Internal Medicine 1997; 126: 946–54.PubMedCrossRefGoogle Scholar
  2. 2.
    Cameron DW, Heath-Chiozzi M, Danner S, et al: Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group. Lancet 1998; 351:543–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Hammer SM, Squires KE, Hughes MD, et al: A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997; 33’7: 725–33.Google Scholar
  4. 4.
    Palella FJ, Jr., Delaney KM, Moorman AC, et al: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853–60.PubMedCrossRefGoogle Scholar
  5. 5.
    Lee LM, Karon JM, Selik R, et al: Survival after AIDS diagnosis in adolescents and adults during the treatment era, United States, 1984–1997. JAMA 2001; 285:1308–1315.Google Scholar
  6. 6.
    Raboud JM, Montaner JS, Conway B, et al.: Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy. AIDS 1998; 12: p] 619–24.CrossRefGoogle Scholar
  7. 7.
    Kempf DJ, Rode RA, Xu Y, et al: The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir. AIDS 1998; 12:F9-F14.CrossRefGoogle Scholar
  8. 8.
    Hirsch MS, Conway B, D’Aquila RT, et al: Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society — USA Panel. JAMA 1998; 279:p 1984–91.PubMedCrossRefGoogle Scholar
  9. 9.
    d’Arminio Monforte A, Testa L, Adorni F, et al.: Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral-experienced patients in advanced stages of HIV-1 infection. AIDS 1998; 12:1631–7.CrossRefGoogle Scholar
  10. 10.
    Volberding PA, Lagakos SW, Koch MA, et al: Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases. N Engl J Med 1990; 322:p 941–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Mulder JW, Cooper DA, Mathiesen L, et al: Zidovudine twice daily in asymptomatic subjects with HIV infection and a high risk of progression to AIDS: a randomized, double-blind placebo-controlled study. The European-Australian Collaborative Group (Study 017). AIDS 1994; 8:313–21.PubMedCrossRefGoogle Scholar
  12. 12.
    Volberding PA, Lagakos SW, Grimes JM, et al.: A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials Group. N Engl J Med 1995; 333:401–7.PubMedCrossRefGoogle Scholar
  13. 13.
    Concorde Coordinating Committee: Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Concorde Coordinating Committee. Lancet 1994;343:871–81.CrossRefGoogle Scholar
  14. 14.
    Kinloch-De Loes S, Hirschel BJ, Hoen B, et al: A controlled trial of zidovudine in primary human immunodeficiency virus infection. N Engl J Med 1995; 333:408–13.PubMedCrossRefGoogle Scholar
  15. 15.
    Lindbäck S, Vizzard J, Cooper DA, Gaines H: Long-term prognosis following Zidovudine monotherapy in primary human immunodeficiency virus type 1 infection. JID 1999; 179:1549–52.PubMedCrossRefGoogle Scholar
  16. 16.
    Murphy RL, Brun S, Hicks C, et al: ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results. AIDS, 2001. 15: p. F1–9.CrossRefGoogle Scholar
  17. 17.
    Rockstroh JK, Bergmann F, Wiesel W, Rieke A, Thiesen A, Fatkenheuer G, Oette M, Carls H, Fenske S, Nadler M, Knechten H: Efficacy and safety of twice daily first-line ritonavir/ indinavir plus double nucleoside combination therapy in HIV-infected individuals. German Ritonavir/Indinavir Study Group. AIDS 2000; 14(9): 1181–5PubMedCrossRefGoogle Scholar
  18. 18.
    Staszewski S, Morales-Ramirez J, Tashima KT, et al: Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HI V-1 infection in adults. N Engl J Med 1999; 341:1865–1873PubMedCrossRefGoogle Scholar
  19. 19.
    Staszewski S, Keiser P, Gathe J, et al: Comparison of antiviral response with abacavir/ combivir to indinavir/combivir in therapy-naive adults at 48 weeks (CNA3005). 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, 1999. (Abstract 505).Google Scholar
  20. 20.
    Ruane P, Parenti D, Hessenthaler S, Shepp D, Spragion D, Kauf T, Yau L, St. Clair M, Goodwin D, Hernandez J for the COL30336 Study Team: The Pl-sparing, compact, quad regimen of Combivir/Abacavir/efavirenz (AOM/ABC/EFV) is potent and well tolerated in naive subjects with high viral loads: 24-week data. 1st IAS Conference on HIV Pathogenesis and Treatment, Buenos Aires, Argentina, July 8–11,2001, Abstract # 221.Google Scholar
  21. 21.
    Back DJ, Gibbons SE, Khoo SH, Merry C, Barry MG, Mulcahy FM. Therapeutic drug monitoring of antiretrovirals: ready for the clinic? J Int Assoc Physicians AIDS Care 2000;6:34–7.Google Scholar
  22. 22.
    Piscitelli S, Bechtel C, Sadler B, Falloon J. The addition of a second protease inhibitor eliminated amprenavir-efavirenz interactions and increased amprenavir concentrations. 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, 2000. (Abstract 90).Google Scholar
  23. 23.
    Saah AJ, Winched G, Seniuk M, Deutsch P. Multiple-dose pharmacokinetics and toler-ability of indinavir-ritonavir combinations in healthy volunteers. 6th Conference on Retroviruses and Opportunistic Infections. Chicago, 1999. (Abstract 136).Google Scholar
  24. 24.
    Cameron DW, Japour AJ, Xu Y, et al: Ritonavir and saquinavir combination therapy for the treatment of HIV infection. AIDS, 1999. 13: p. 213–224.PubMedCrossRefGoogle Scholar
  25. 25.
    Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989;243:1731–1734.PubMedCrossRefGoogle Scholar
  26. 26.
    D’Aquila RT, Johnson VA, Welles SL, et al: Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. Ann Intern Med 1995;122:401–408.PubMedCrossRefGoogle Scholar
  27. 27.
    DeGruttola V, Dix L, A’Aquila R, et al.: The relationship between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antiviral Therapy 2000;5:43–50.Google Scholar
  28. 28.
    Durant J, Clevenbergh F, Halfon F, et al: Drug-resistance genotyping in HIV-l therapy: the VIRADAPT randomised controlled trial. Lancet 1999;353:2195–2199.PubMedCrossRefGoogle Scholar
  29. 29.
    Baxter JD, Mayers DL, Wentworth DN, et al: A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS 2000; 14(9):F83–93.CrossRefGoogle Scholar
  30. 30.
    Cingolani A, Antinori A, Rizzo MG, et al: Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS 2002; 16:369–379.PubMedCrossRefGoogle Scholar
  31. 31.
    Tural C, Ruiz L, Holtzer C, et al.: Clinical utility of HIV-l genotyping and expett advice: the Havana trial. AIDS 2002; 16: 209–218.PubMedCrossRefGoogle Scholar
  32. 32.
    Cohen CJ, Hunt S, Sension M, Farthing C, Conant M, Jacobson S, Nadler J, Verbiest W, Hertogs K, Ames M, Rinehart AR, Graham NM; VIRA300J Study Team. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS 2002;16:579–88PubMedCrossRefGoogle Scholar
  33. 33.
    Meynard JL, Vray M, Morand-Joubert L, et al: Impact of treatment guided by phenotypic or genotypic resistance tests on the response to antiretroviral therapy: a randomized trial (NARVAL, ANRS 088). Antiviral Therapy 2000;5 suppl 3:67–68,Google Scholar
  34. 34.
    The Euro Guideline s Group for HIV Resistance. Clinical and laboratory guideline.-; for the use of HIV-l drug resistance testing as part of treatment management: recommendations for the European setting. The EuroGuidelines Group for HIV resistance. AIDS 2001;15:309–320.CrossRefGoogle Scholar
  35. 35.
    Carpenter CC, Cooper DA, Fischl MA, et al : Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA 2000; 283: 381–390.PubMedCrossRefGoogle Scholar
  36. 36.
    Duwe S, Brunn M, Altmann D, et al: Frequency of genotypic and phenotypic drug-resistant HIV-l among therapy-naive patients of the German Seroconverter Study. J Acquir Immune Defic Syndr 2001;26: 266–273.PubMedCrossRefGoogle Scholar
  37. 37.
    Acosta EP, Henry K, Baken L, Page LM, Fletcher CV. Indinavir concentrations and antiviral effect. Pharmacotherapy 1999; 19: 708–712.PubMedCrossRefGoogle Scholar
  38. 38.
    Burger DM, Hoetelmans RMW, Mulder JW, et al: Low plasma levels of indinavir (IDV) are highly predictive of virological treatment failure in patients using IDV-containing triple therapy. 12th World AIDS Conference, Geneva, June 28-July 3, 1998: Abstr. 828Google Scholar
  39. 39.
    Acosta EP. The promise of therapeutic drug monitoring in HIV infection. August 1999. ( html) (See NAPS document no. 05584 for 5 pages, c/o Microfiche Publications, 248 Hempstead Tpke., West Hempstead, NY l 1552.)Google Scholar
  40. 40.
    Piscitelli SC The limited value of therapeutic drug monitoring in HIV infection. August 1999. ( (See NAPS document no. 05584 for 4 pages, c/o Microfiche Publications, 248 Hempstead Tpke., West Hempstead, NY 11552.)Google Scholar
  41. 41.
    Niehues T, Wintergerst U, Funk M, Notheis G et al.: Empfehlungen zur antiretroviralen Therapie bei HIV-infizierten Kindern. Mo-natsschr Kinderheilkd 2001; 149:1372–82,CrossRefGoogle Scholar
  42. 42.
    Deutsch-Österreichische Empfehlungen zur HIV-Therapie in der Schwangerschaft. Aktualisierung Mai 2001. BR_LINIE/BR_LINIE.HTMGoogle Scholar
  43. 43.
    Postexpositionelle Prophylaxe nach HIV-Exposition, Deutsch-Österreichische Empfehlungen. Aktualisierung Mai 2002.

Copyright information

© Springer-Verlag Berlin Heidelberg 2003

Authors and Affiliations

  • J. L’age-Stehr
  • E. B. Helm
  • H. D. Peters
  • L. Nolde

There are no affiliations available

Personalised recommendations